01 / EXECUTIVE SUMMARY
Europol supported a six-country operation against a network producing, distributing and selling counterfeit medicines and supplements through misleading campaigns presenting products as genuine treatments.
02 / WHAT HAPPENED
Europol supported a six-country operation against a network producing, distributing and selling counterfeit medicines and supplements through misleading campaigns presenting products as genuine treatments.
The chain distinguishes what appeared valid, what was physically true, which authority followed and what consequence the source documents.
Marketing campaigns and alleged legitimate producers presented illicit products as genuine treatments for serious diseases.
Authorities identified illegally produced medicines and supplements, including a central warehouse and more than 300 product types.
Consumers and distribution channels were induced to purchase and accept the products as treatments.
Europol reported EUR 240 million in illicit transactions, 138 searches, at least nine arrests and assets worth at least EUR 17.7 million seized.
Issuer-verified provenance from approved manufacturer and batch to the physical package offered to the patient.
ECR separates a documented monetary floor from a modeled social and economic consequence envelope. It is not an accounting loss figure.
The range combines documented facts with calibrated consequence and response-cost assumptions; it is not an accounting loss figure.
Operational and financial figures are Europol disclosures; 4SI supplies the Presence analysis.
Records and packaging cannot establish the presence of the expected medicine on their own.
4SI does not claim to have independently verified the underlying event. Scores, boundary analysis and economic ranges interpret published evidence; they are not probabilities, compliance findings, valuations or loss forecasts.
Related cases are editorially connected by domain, authority pattern or missing physical trust boundary.